TRC105

Known as: Anti-Endoglin Chimeric Monoclonal Antibody TRC105 
A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Anti… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
0246820092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OBJECTIVE TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open-label study… (More)
Is this relevant?
2015
2015
BACKGROUND Endoglin is an endothelial cell membrane receptor essential for angiogenesis and highly expressed on the vasculature… (More)
Is this relevant?
2014
2014
Endoglin, or CD105, is a cell membrane glycoprotein that is overexpressed on proliferating endothelial cells (EC), including… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
TRC105 is an endoglin-targeting drug that possesses anti-angiogenic and antitumor potential. Analysis of the initial phase I… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Multifunctional mesoporous silica nanoparticles (MSN) with well-integrated multimodality imaging properties have generated… (More)
Is this relevant?
2014
2014
PURPOSE Endoglin, an endothelial cell membrane receptor expressed on angiogenic tumor vessels, is essential for angiogenesis and… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2013
2013
The goal of this study was to assess ischemia-induced angiogenesis with (64)Cu-NOTA-TRC105 positron emission tomography (PET) in… (More)
Is this relevant?
2013
2013
Biological changes following myocardial infarction (MI) lead to increased secretion of angiogenic factors that subsequently… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase I, open-label study… (More)
  • table 1
  • figure 1
  • table 3
  • figure 2
  • figure 3
Is this relevant?
2011
2011
High tumor microvessel density correlates with a poor prognosis in multiple solid tumor types. The clinical gold standard for… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?